The addition of lenvatinib and pembrolizumab to chemotherapy did not extend OS for certain patients with advanced ...

Armando, a 71-year-old with an active lifestyle, was midway through a round of golf when a strange sensation crept into his ...

Stifel analysts reiterated a Buy rating on Bicara Therapeutics Inc (NASDAQ:BCAX), maintaining a $47.00 price target. Trading ...

The LEAP-015 study is evaluating Merck's Keytruda and Eisai's Lenvima plus chemotherapy in certain types of gastroesophageal ...

(RTTNews) - Bicara Therapeutics Inc. (BCAX), Monday announced the results from the Phase 1/1b dose expansion cohort, evaluating the combination of ficerafusp alfa with pembrolizumab in patients with ...

High disease control rate and strong interim safety results observed in pancreatic cancer patients across three trials ...

The company announced interim data showing strong systemic responses in its safety and efficacy study combining Alpha DaRT treatment with ...

Neoadjuvant Keytruda for patients with deficient DNA mismatch repair colon cancer resulted in a pathological complete ...

The phase 3 LEAP-015 trial evaluated the efficacy and safety of pembrolizumab with lenvatinib in patients with advanced/metastatic gastroesophageal cancer.

Research has introduced daromun, therapeutic vaccines, and novel combinations for metastatic melanoma, reshaping the ...

In an ongoing adaptive-design trial exploring different combinations of neoadjuvant immunotherapies including the anti-PD-1 agent pembrolizumab, the anti-TIGIT agent vibostolimab and the oncolytic ...

The addition of lenvatinib/pembrolizumab to TACE showed a numerical improvement in PFS, but longer follow-up is necessary to ...